Issues
-
Cover Image
Cover Image
Intralesional administration of interleukin-2 (IL2) is one of many immuno-oncology approaches for treating patients with metastatic melanoma. Using multiomic and spatial analysis of matched untreated and IL2-injected lesions from seven patients with metastatic melanoma, Pourmaleki et al. identify molecular and cellular changes associated with response to therapy. For example, complete regression following intralesional administration of IL2 was associated with pretreatment expression of MHC class I by tumor cells, proliferating PD-1+LAG-3+TIM-3+CD8+ T cells, and stromal B-cell aggregates. The data highlight how a multidimensional approach can be used to identify potential biomarkers of immunotherapy response for further investigation. Read more in this issue on page 303. Original image from Supplementary Fig. S1B. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
What We're Reading
In the Spotlight
Review
Priority Brief
Research Articles
Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia
Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma
Accounting for B-cell Behavior and Sampling Bias Predicts Anti–PD-L1 Response in Bladder Cancer
Tumor Necrosis Factor-α–Induced Protein 8-Like 2 Fosters Tumor-Associated Microbiota to Promote the Development of Colorectal Cancer
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.